|
|
| BC | supplementation |
| placebo |
|
|
|
|
| Baseline | 4 months | d | Baseline | 4 months | d |
| BAP (ng/L) | Normal | 278.8 ± 62.8 | 291.4 ± 76.0 | 0.17 | 278.7 ± 78.2 | 265.6 ± 100.4 | 0.14 |
|
| Osteopenia | 202.8 ± 74.1 | 200.8 ± 75.8 | 0.03 | 260.6 ± 137.1 | 274.6 ± 105.7 | 0.11 |
|
| Osteporosis | 239.1 ± 48.4 | 219.1 ± 60.2 | 0.34 | 332.3 ± 173.0 | 223.3 ± 30.3a | 0.70 |
| Osteocalcin (ng/L) | Normal | 7.7 ± 3.9 | 7.5 ± 4.9 | 0.03 | 8.9 ± 6.4 | 9.2 ± 8.9 | 0.04 |
|
| Osteopenia | 10.3 ± 6.9 | 10.0 ± 5.0 | 0.05 | 13.8 ± 5.8 | 13.7 ± 6.2 | 0.00 |
|
| Osteporosis | 9.2 ± 5.4 | 8.3 ± 4.7 | 0.16 | 19.8 ± 4.2 | 16.3 ± 5.6 | 0.57 |
| DPD (ng/L) | Normal | 56.3 ± 2.2 | 59.0 ± 5.5 | 0.59 | 59.3 ± 2.1 | 58.2 ± 3.5 | 0.38 |
|
| Osteopenia | 59.1 ± 5.6 | 61.8 ± 4.9 | 0.48 | 61.1 ± 4.5 | 61.0 ± 4.6 | 0.02 |
|
| Osteporosis | 61.5 ± 2.1 | 64.8 ± 4.9 | 0.77 | 57.4 ± 4.3 | 59.6 ± 9.4 | 0.25 |
| CTX-I (ng/L) | Normal | 4.5 ± 0.4 | 4.5 ± 0.5 | 0.03 | 4.5 ± 0.5 | 4.6 ± 0.5 | 0.04 |
|
| Osteopenia | 4.7 ± 0.3 | 4.6 ± 0.4 | 0.03 | 4.1 ± 0.5 | 4.4 ± 0.4 | 0.00 |
|
| Osteporosis | 4.3 ± 0.5 | 4.7 ± 0.3a | 0.16 | 4.4 ± 0.3 | 4.7 ± 0.4a | 0.57 |